PRESENTATIONNATION

PRESENTATIONNATION

Browse a growing database of presentations shared by companies worldwide.

Browse

Browse All
All Companies
Presentations
Infographics
Reports
Brochures

Company

Blog
About
Contact

Legal

Privacy Policy
Terms of Service

© 2026 Presentation Nation. All rights reserved.
Built in San Diego by Twenty6 Red, Inc.

Envista Holdings_October_2019_405_47405 - Envista Holdings | Presentation Nation

HomepageEnvista HoldingsEnvista Holdings_October_2019_405_47405

Envista Holdings_October_2019_405_47405

Envista Holdings

Browse presentations, reports, and documents from Envista Holdings.

Tags

2019

Filter options

All (17)●
brochure (1)○
earnings (1)○
presentation (15)○

Get the best presentations in your inbox

Join professionals who get a weekly curated collection of top business presentations, investor decks, and industry reports — free.

No spam. Unsubscribe anytime.

Loading viewer...

presentation

Format: PDF presentation

Share:

Envista Holdings_October_2019_405_47405 by Envista Holdings Corporation.

Browse all presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Envista Holdings

2022-04-01 - Envista Summit - Investor Day - Full Presentation _FINAL

presentation

2023-02-24%20-%20Investor%20Access%20%40%20Envista%20Summit%20-%20Final

presentation

Similar presentations from other companies

2023_unified_commerce_benchmark_incisiv_googlecloud_manhattan_zebra

presentation

Manhattan Associates

DraftKings__2023__403_97403

presentation

DraftKings

2024-01-08%20-%20JP%20Morgan%20Presentation%20-%20Envista

presentation

2024-Q1%20-%20NVST%20-%20Investor%20Presentation%20-%20Final

presentation

2024-Q2+-+NVST+-+Earnings+Presentation+-Final

presentation

Envista__2023__149_95149

presentation

SpartanNash_February_2022_902_79902

presentation

SpartanNash Co

Atkore_May_2018_49_27049

presentation

Atkore

The Chemours Company_November_2018_485_35485

presentation

The Chemours Company

Blueprint-Medicines-ASCO-2023-BLU-945-EGFRmNSCLC-Monotherapy-Combination-Osimertinib-Short-Oral

presentation

Blueprint Medicines Corporation